Benign prostatic hyperplasia: caveat for finasteride should be discussed before prescribing

BMJ. 2006 Sep 23;333(7569):654; author reply 654. doi: 10.1136/bmj.333.7569.654.
No abstract available

Publication types

  • Comment
  • Letter

MeSH terms

  • Antineoplastic Agents / therapeutic use*
  • Finasteride / therapeutic use*
  • Humans
  • Male
  • Prostate-Specific Antigen / blood
  • Prostate-Specific Antigen / drug effects
  • Prostatic Hyperplasia / drug therapy*
  • Prostatic Neoplasms / diagnosis*
  • Prostatic Neoplasms / prevention & control
  • Randomized Controlled Trials as Topic

Substances

  • Antineoplastic Agents
  • Finasteride
  • Prostate-Specific Antigen